Last reviewed · How we verify
Nipocalimab SC-LIV
Nipocalimab is a subcutaneous monoclonal antibody that blocks neonatal Fc receptor (FcRn) to reduce pathogenic immunoglobulin levels in autoimmune conditions.
Nipocalimab is a subcutaneous monoclonal antibody that blocks neonatal Fc receptor (FcRn) to reduce pathogenic immunoglobulin levels in autoimmune conditions. Used for Generalized myasthenia gravis (gMG), IgG-mediated autoimmune conditions.
At a glance
| Generic name | Nipocalimab SC-LIV |
|---|---|
| Sponsor | Janssen Research & Development, LLC |
| Drug class | FcRn inhibitor |
| Target | Neonatal Fc receptor (FcRn) |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
FcRn is responsible for recycling and extending the half-life of immunoglobulins, particularly IgG. By blocking FcRn, nipocalimab reduces circulating levels of pathogenic antibodies, thereby decreasing autoimmune-mediated tissue damage. This mechanism is particularly relevant in antibody-mediated autoimmune diseases such as myasthenia gravis.
Approved indications
- Generalized myasthenia gravis (gMG)
- IgG-mediated autoimmune conditions
Common side effects
- Infection
- Upper respiratory tract infection
- Injection site reactions
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Nipocalimab SC-LIV CI brief — competitive landscape report
- Nipocalimab SC-LIV updates RSS · CI watch RSS
- Janssen Research & Development, LLC portfolio CI